DDInter1643 DDInter1676
Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate. RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. Subcutaneous administration of sarilumab has been shown to decrease acute-phase reactant levels and improve clinical RA symptoms.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Sarilumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Sarilumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Sarilumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Sarilumab {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Sarilumab {u} may lead to a major life threatening interaction when taken with {v} Smallpox (Vaccinia) Vaccine, Live
Sarilumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone
Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Sarilumab may lead to a major life threatening interaction when taken with Cladribine
Sarilumab may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live